

April 1, 2024 Full Updates for the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit Supplement (HSDBS)* and *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Please be advised that the annual April 1, 2024 Full Updates to the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit List (HSDBS)* and the *Palliative Coverage Drug Benefit Supplement (PCDBS)* have been posted online at ab.bluecross.ca/dbl/publications.php.

Effective April 1, 2024, the following Drug Products will be removed from the *ADBL* as the manufacturer did not submit a price to the annual Alberta Price Confirmation process:

As per the Alberta Price Policy, Manufacturers with Drug Products currently listed on the *ADBL* were invited to re-quote the price of their Drug Product(s) for continual listing. Please be advised that the following Drug Products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective **April 1, 2024**, as these Manufacturers have chosen not to re-confirm their price.

All Drug Products scheduled to be removed from the *ADBL* have been identified as having therapeutic alternatives. *Effective April 1, 2024*, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A 30-day transition period will be applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of **May 1, 2024**, claims will no longer pay for these products.

Patients impacted by the removal of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/NPN	Product Description
00002483874	Budesonide 3 mg Controlled-Release Capsule
00002455609	Cholestyramine-Odan Light 4 G/Oral Powder Packet
00000444995	Medisure Blood Glucose Test Strips
00000445006	Medisure Empower Blood Glucose Test Strips
00000890960	Olestyr Light 4 G/Oral Powder Packet
00002210320	Olestyr Regular 4 G/Oral Powder Packet
00000999788	Similac Alimentum Infant Formula Powder

continued next page

continued from previous page

Additionally, effective April 1, 2024, the following Drug Products will be removed from the ADBL as these Drug Products have been discontinued by the manufacturer:

The Alberta government-sponsored drug programs previously covered the following Drug Products; however, notification of discontinuation has been received from the Manufacturers. Effective **April 1, 2024**, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will apply and, as of **May 1, 2024**, claims will no longer pay for these products. Patients impacted by the discontinuation of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/NPN	Product Description
00002447207	Bio-Quetiapine 100 mg Tablet
00002447223	Bio-Quetiapine 200 mg Tablet
00002447258	Bio-Quetiapine 300 mg Tablet
00001916858	Clavulin-500F Tablet
00002238829	Clavulin-875 Tablet
00000873454	Eryc 333 mg Capsule (Enteric-Coated Pellet)
00002230898	Foradil 12 mcg Dry Powder Inhalation Capsule
00002350459	Glyburide 2.5 mg Tablet
00002243297	Glucagon 1 mg/Vial Injection
00000999890	Isosource 1.0 HP Oral Liquid
00002131064	Lioresal Intrathecal 2 mg/ml Injection
00002471388	M-Clarithromycin 250 mg tablet
00002350750	Naproxen 250 mg Tablet
00002350769	Naproxen 375 mg tTablet
00002350793	Naproxen EC 375 mg Enteric-Coated Tablet
00002350807	Naproxen EC 500 mg Enteric-Coated Tablet
00002351021	Naproxen Sodium DS 550 mg Tablet
00002449781	Nucala 100 mg/ml (144 mg/Vial) Reconstituted Injection
00002401312	Piperacillin and Tazobactam 2 G/250 mg Vial Injection
00002401320	Piperacillin and Tazobactam 3 G/375 mg Vial Injection
00002401339	Piperacillin and Tazobactam 4 G/500 mg Vial Injection
00002477173	pms-Atorvastatin 80 mg Tablet
00000550086	Septra Injection
00000578576	Stieva-A 0.025% Topical Cream
00000518182	Stieva-A 0.05% Topical Cream
00002275023	Teva-Venlafaxine XR 37.5 mg Extended-Release Capsule
00002240432	Teveten 400 mg Tablet
00002243942	Teveten 600 mg Tablet
00002253631	Teveten Plus Tablet

continued next page

PHARMACY BENEFACT

continued from previous page

DIN/NPN	Product Description
00002241227	Transdermal Nicotine 7mg/ Day (17.5 mg/pth) Patch
00002241226	Transdermal Nicotine 14 mg/ Day (35 mg/pth) Patch
00002241228	Transdermal Nicotine 21 mg/ Day (52.5 mg/pth) Patch
00002470632	Trispan 20 mg/ml Injection
0000999422	Vivonex Pediatric Oral Powder
00002213567	Zofran 4 mg Tablet
00002213575	Zofran 8 mg Tablet

For a summary of all updates, please refer to the April 1, 2024 Summary of Changes for highlights of products and pricing changes.

Please note that the online interactive *Drug Benefit List (iDBL)* is available at ab.bluecross.ca/dbl/idbl_main1.php; this is a near real-time application and as such, contains the most up-to-date information.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

